Cel Sci Corporation (CVM)

[Foxwoods Man]

The problem with the Yahoo 1 yr. target of $7 is that is a running 1 year. I swear it has been at $7 for at least a year already....

Marketwatch also has one analyst giving it a $7 target but they might be using the Yahoo figure..

Reuters has it as "outperform" as of August 1 this year

I did find one analyst report from January of this year that gave a target price of $7.33 (nice to be that precise)...here is an excerpt from that report:

Many other pre-revenue biotech stocks with lead drugs developments in Phase III trials, like Synta Pharmaceuticals (SNTA) or NewLink Genetics (NLNK), are awarded high valuations by investors, ranging from $400 million to over $1 billion. Given that CEL-SCI’s lead drug is also in Phase III trials, and with a high possibility of approval, CEL-SCI’s current $53 million valuation is low. Given our estimate, the value should be closer to $365 million. Which would be line with other pre-revenue biotech stocks and in line with the potential shown by Multikine, and the confidence in the drug’s potential shown by Ergomed’s funding decision.

Given our estimated value and the diverse portfolio of IP held by the company, we estimate the value to be in the region of $7.33 per share. This represents a current market under-pricing of nearly 585%. We therefore recommend that the stock should be a strong BUY.

Summary


The IP portfolio that CVM has, the stage of FDA approval, and the confidence in Multikine shown by Ergomed, gives us an estimated price per share of $7.33. This leads us to recommend that the company should be a strong BUY.